203 related articles for article (PubMed ID: 25229183)
21. Targeting essential cell wall lipase Rv3802c for potential therapeutics against tuberculosis.
Saravanan P; Avinash H; Dubey VK; Patra S
J Mol Graph Model; 2012 Sep; 38():235-42. PubMed ID: 23085165
[TBL] [Abstract][Full Text] [Related]
22. Structure of the mycosin-1 protease from the mycobacterial ESX-1 protein type VII secretion system.
Solomonson M; Huesgen PF; Wasney GA; Watanabe N; Gruninger RJ; Prehna G; Overall CM; Strynadka NC
J Biol Chem; 2013 Jun; 288(24):17782-90. PubMed ID: 23620593
[TBL] [Abstract][Full Text] [Related]
23. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance.
Perola E; Walters WP; Charifson PS
Proteins; 2004 Aug; 56(2):235-49. PubMed ID: 15211508
[TBL] [Abstract][Full Text] [Related]
24. Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.
Ramakrishnan G; Chandra NR; Srinivasan N
Mol Biosyst; 2015 Dec; 11(12):3316-31. PubMed ID: 26429199
[TBL] [Abstract][Full Text] [Related]
25. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
[TBL] [Abstract][Full Text] [Related]
26. Shape-based virtual screening, docking, and molecular dynamics simulations to identify Mtb-ASADH inhibitors.
Kumar R; Garg P; Bharatam PV
J Biomol Struct Dyn; 2015; 33(5):1082-93. PubMed ID: 24875451
[TBL] [Abstract][Full Text] [Related]
27. Beware of machine learning-based scoring functions-on the danger of developing black boxes.
Gabel J; Desaphy J; Rognan D
J Chem Inf Model; 2014 Oct; 54(10):2807-15. PubMed ID: 25207678
[TBL] [Abstract][Full Text] [Related]
28. Fragment-Based Design of
Sabbah M; Mendes V; Vistal RG; Dias DMG; Záhorszká M; Mikušová K; Korduláková J; Coyne AG; Blundell TL; Abell C
J Med Chem; 2020 May; 63(9):4749-4761. PubMed ID: 32240584
[TBL] [Abstract][Full Text] [Related]
29. Pharmacophore and Docking Based Virtual Screening of Validated Mycobacterium tuberculosis Targets.
Vyas R; Karthikeyan M; Nainaru G; Muthukrishnan M
Comb Chem High Throughput Screen; 2015; 18(7):624-37. PubMed ID: 26138571
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophore based virtual screening, synthesis and SAR of novel inhibitors of Mycobacterium sulfotransferase.
Saha R; Tanwar O; Alam MM; Zaman MS; Khan SA; Akhter M
Bioorg Med Chem Lett; 2015 Feb; 25(3):701-7. PubMed ID: 25541388
[TBL] [Abstract][Full Text] [Related]
31. Resisting resistant Mycobacterium tuberculosis naturally: mechanistic insights into the inhibition of the parasite's sole signal peptidase Leader peptidase B.
Dhiman H; Dhanjal JK; Sharma S; Chacko S; Grover S; Grover A
Biochem Biophys Res Commun; 2013 Apr; 433(4):552-7. PubMed ID: 23510997
[TBL] [Abstract][Full Text] [Related]
32. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
Deng Z; Chuaqui C; Singh J
J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
[TBL] [Abstract][Full Text] [Related]
33. Discovery of novel MDR-Mycobacterium tuberculosis inhibitor by new FRIGATE computational screen.
Scheich C; Szabadka Z; Vértessy B; Pütter V; Grolmusz V; Schade M
PLoS One; 2011; 6(12):e28428. PubMed ID: 22164290
[TBL] [Abstract][Full Text] [Related]
34. Structure-based design of diverse inhibitors of Mycobacterium tuberculosis N-acetylglucosamine-1-phosphate uridyltransferase: combined molecular docking, dynamic simulation, and biological activity.
Soni V; Suryadevara P; Sriram D; ; Kumar S; Nandicoori VK; Yogeeswari P
J Mol Model; 2015 Jul; 21(7):174. PubMed ID: 26078037
[TBL] [Abstract][Full Text] [Related]
35. Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.
Stigliani JL; Bernardes-Génisson V; Bernadou J; Pratviel G
Org Biomol Chem; 2012 Aug; 10(31):6341-9. PubMed ID: 22751934
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
Saxena S; Abdullah M; Sriram D; Guruprasad L
J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
[TBL] [Abstract][Full Text] [Related]
37. Nonlinear scoring functions for similarity-based ligand docking and binding affinity prediction.
Brylinski M
J Chem Inf Model; 2013 Nov; 53(11):3097-112. PubMed ID: 24171431
[TBL] [Abstract][Full Text] [Related]
38. The putative propeptide of MycP1 in mycobacterial type VII secretion system does not inhibit protease activity but improves protein stability.
Sun D; Liu Q; He Y; Wang C; Wu F; Tian C; Zang J
Protein Cell; 2013 Dec; 4(12):921-31. PubMed ID: 24248472
[TBL] [Abstract][Full Text] [Related]
39. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling.
Meslamani J; Li J; Sutter J; Stevens A; Bertrand HO; Rognan D
J Chem Inf Model; 2012 Apr; 52(4):943-55. PubMed ID: 22480372
[TBL] [Abstract][Full Text] [Related]
40. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
